Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level
Year: 2025
Type: other
Abstract: Objective: The Center for Medicare and Medicaid Services (CMS) requires a low C-peptide level for insulin pump coverage unless the individual is beta cell autoantibody positive, which precludes coverage of automated insulin delivery (AID) systems for many people with type 2 diabetes. Research Design and Methods: In the 2IQP randomized trial evaluating the t:slim X2 insulin pump with Control-IQ+ technology, adults with insulin-treated type 2 diabetes were categorized into ‘high C peptide’ (N=195) and ‘low C-peptide’ (N=59) groups based on CMS criteria. Results: In the AID group, mean HbA1c decreased from baseline by 0.8% which was significantly greater than the control group with both high (P<0.001) and low C-peptide (P=0.02). Results were similar in participants ≥65 years old. Conclusions: The benefit of AID is present with high and low C-peptide levels. Thus, requiring a low C-peptide level as a prerequisite for AID therapy is not warranted.
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4414194532
Cites:
Cited by:
Related to: